86 related articles for article (PubMed ID: 38659056)
21. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches.
Zuber V; Grinberg NF; Gill D; Manipur I; Slob EAW; Patel A; Wallace C; Burgess S
Am J Hum Genet; 2022 May; 109(5):767-782. PubMed ID: 35452592
[TBL] [Abstract][Full Text] [Related]
22. Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.
Ouyang Y; Chen Y; Chen K; Tang Z; Shi G; Qu C; Zhang K; Yang H
Hum Genomics; 2024 Apr; 18(1):43. PubMed ID: 38659056
[TBL] [Abstract][Full Text] [Related]
23. Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.
Li J; Wang F; Li Z; Feng J; Men Y; Han J; Xia J; Zhang C; Han Y; Chen T; Zhao Y; Zhou S; Da Y; Chai G; Hao J
J Transl Med; 2024 Mar; 22(1):302. PubMed ID: 38521921
[TBL] [Abstract][Full Text] [Related]
24. Mendelian randomization analysis identifies druggable genes and drugs repurposing for chronic obstructive pulmonary disease.
Wang Z; Li S; Cai G; Gao Y; Yang H; Li Y; Liang J; Zhang S; Hu J; Zheng J
Front Cell Infect Microbiol; 2024; 14():1386506. PubMed ID: 38660492
[TBL] [Abstract][Full Text] [Related]
25. Unveiling potential drug targets for hyperparathyroidism through genetic insights via Mendelian randomization and colocalization analyses.
Chen B; Wang L; Pu S; Guo L; Chai N; Sun X; Tang X; Ren Y; He J; Hao N
Sci Rep; 2024 Mar; 14(1):6435. PubMed ID: 38499600
[TBL] [Abstract][Full Text] [Related]
26. TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.
Duan QQ; Wang H; Su WM; Gu XJ; Shen XF; Jiang Z; Ren YL; Cao B; Li GB; Wang Y; Chen YP
BMC Med; 2024 Mar; 22(1):96. PubMed ID: 38443977
[TBL] [Abstract][Full Text] [Related]
27. Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.
Li X; Shen A; Zhao Y; Xia J
Schizophr Bull; 2023 Sep; 49(5):1305-1315. PubMed ID: 37418754
[TBL] [Abstract][Full Text] [Related]
28. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
Yan C; Yue Y; Guan Y; Bu B; Ke Q; Duan R; Deng H; Xue Q; Jiang H; Xiao F; Yang H; Chang T; Zou Z; Li H; Tan S; Xiao H; Zhou H; Zhang H; Meng Q; Li W; Li W; Guo J; Zhang Y; Li Z; Tu J; Shi J; Li W; Lee M; Chen Y; Tao X; Zhao S; Li P; Zhao C;
JAMA Neurol; 2024 Mar; 81(4):336-45. PubMed ID: 38436998
[TBL] [Abstract][Full Text] [Related]
29. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Sheikh SZ; Scheinberg MA; Wei JC; Tegzova D; Stohl W; de Toledo RA; Mucenic T; Banfi MRA; Maksimowicz-McKinnon K; Abud-Mendoza C; Navarra S; Garcia M; Garcia-De La Torre I; Ros JO; Levy RA; Bass DL; Terrés JR; Punwaney R; Harris J; Nami A; Pierce A; Thorneloe KS; Ji B; Roth DA
Lancet Rheumatol; 2021 Feb; 3(2):e122-e130. PubMed ID: 38279368
[TBL] [Abstract][Full Text] [Related]
30. Protein-centric omics integration analysis identifies candidate plasma proteins for multiple autoimmune diseases.
Chen Y; Liu S; Gong W; Guo P; Xue F; Zhou X; Wang S; Yuan Z
Hum Genet; 2023 Dec; ():. PubMed ID: 38143258
[TBL] [Abstract][Full Text] [Related]
31. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies.
Ren Y; Chen S; Yang H
Front Immunol; 2023; 14():1279808. PubMed ID: 37965304
[TBL] [Abstract][Full Text] [Related]
33. Plasma proteomic associations with genetics and health in the UK Biobank.
Sun BB; Chiou J; Traylor M; Benner C; Hsu YH; Richardson TG; Surendran P; Mahajan A; Robins C; Vasquez-Grinnell SG; Hou L; Kvikstad EM; Burren OS; Davitte J; Ferber KL; Gillies CE; Hedman ÅK; Hu S; Lin T; Mikkilineni R; Pendergrass RK; Pickering C; Prins B; Baird D; Chen CY; Ward LD; Deaton AM; Welsh S; Willis CM; Lehner N; Arnold M; Wörheide MA; Suhre K; Kastenmüller G; Sethi A; Cule M; Raj A; ; ; ; ; ; ; ; ; ; Burkitt-Gray L; Melamud E; Black MH; Fauman EB; Howson JMM; Kang HM; McCarthy MI; Nioi P; Petrovski S; Scott RA; Smith EN; Szalma S; Waterworth DM; Mitnaul LJ; Szustakowski JD; Gibson BW; Miller MR; Whelan CD
Nature; 2023 Oct; 622(7982):329-338. PubMed ID: 37794186
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
Xu D; Fang J; Zhang S; Huang C; Huang C; Qin L; Li X; Chen M; Liu X; Liu Y; Li Z; Hu J; Bao C; Wei W; Tian J; Duan X; Zeng X
Rheumatology (Oxford); 2024 Mar; 63(3):698-705. PubMed ID: 37399108
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
[TBL] [Abstract][Full Text] [Related]
37. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.
Lin J; Zhou J; Xu Y
Brain; 2023 Aug; 146(8):3364-3372. PubMed ID: 36864689
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
